Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity
Dong Dong,1,2,* Cheng-Hui Hsiao,3,* Beppino C Giovanella,4,† Yifei Wang,2 Diana SL Chow,3 Zhijie Li11International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China; 2GuangZhou (Jinan) Biomedical Research and Development Cente...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ad81c71594a64c578accf6db73e8b5ae |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ad81c71594a64c578accf6db73e8b5ae |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ad81c71594a64c578accf6db73e8b5ae2021-12-02T06:26:30ZSustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity1178-2013https://doaj.org/article/ad81c71594a64c578accf6db73e8b5ae2019-05-01T00:00:00Zhttps://www.dovepress.com/sustained-delivery-of-a-camptothecin-prodrug-cz48-by-nanosuspensions-w-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Dong Dong,1,2,* Cheng-Hui Hsiao,3,* Beppino C Giovanella,4,† Yifei Wang,2 Diana SL Chow,3 Zhijie Li11International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China; 2GuangZhou (Jinan) Biomedical Research and Development Center Co. Ltd, Guangzhou, China; 3Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA; 4CHRISTUS Stehlin Foundation for Cancer Research, Houston, TX, USA*These authors contributed equally to this work†Dr Beppino C Giovanella passed away in 2017.Background and aim: We have synthesized a novel lactone-stabilized camptothecin (CPT) analog named CZ48 and demonstrated its potent anticancer effects via bioconversion to the active CPT in earlier studies. Herein, we aimed to develop, optimize and characterize CZ48 nanosuspensions, for a sustained delivery of this drug in humans with an intravenous (i.v.) administration.Methods and materials: A three-factor, five-level central composite design (CCD) was employed to establish the impacts of the critical influencing factors (concentrations (wt%) of CZ48, polysorbate 80 (Tween-80), and Pluronic®, F-108 (F-108)) on the responses (particle size and zeta potential). Based on the quantitative influencing factor–response relationships, two optimized CZ48 nanosuspensions of 197.22 ± 7.12 nm (NS-S) and 589.35 ± 23.27 nm (NS-L) were developed with the zeta potential values of –26.5 mV and –27.9 mV, respectively.Results: CZ48 released from the nanosuspensions in a sustained manner in contrast to the rapid release from cosolvent in both PBS and human plasma. Moreover, NS-S exhibited more favored pharmacokinetic properties than NS-L, with a 31-fold prolonged elimination half-life of CPT, and a 2.4-fold enhanced CPT exposure over cosolvent. In efficacy study, NS-S exhibited significant tumor suppression and an improved survival rate with a higher tolerable dose, compared to CZ48 cosolvent.Conclusion: We have successfully developed CZ48 nanosuspensions with significantly favorable pharmacokinetics and improved efficacy using CCD approach. The formulation offers potential merits as a preferred candidate for clinical trials with the prolonged CPT exposure, which is known to correlate with the clinical efficacy.Keywords: sustained drug delivery, CZ48, camptothecin, nanosuspension, anticancerDong DHsiao CHGiovanella BCWang YChow DSLLi ZDove Medical Pressarticlesustained drug deliveryCZ48camptothecinCPTnanosuspensionpharmacokineticsanticancerefficacyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 3799-3817 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
sustained drug delivery CZ48 camptothecin CPT nanosuspension pharmacokinetics anticancer efficacy Medicine (General) R5-920 |
| spellingShingle |
sustained drug delivery CZ48 camptothecin CPT nanosuspension pharmacokinetics anticancer efficacy Medicine (General) R5-920 Dong D Hsiao CH Giovanella BC Wang Y Chow DSL Li Z Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| description |
Dong Dong,1,2,* Cheng-Hui Hsiao,3,* Beppino C Giovanella,4,† Yifei Wang,2 Diana SL Chow,3 Zhijie Li11International Ocular Surface Research Center and Institute of Ophthalmology, Jinan University Medical School, Guangzhou, China; 2GuangZhou (Jinan) Biomedical Research and Development Center Co. Ltd, Guangzhou, China; 3Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA; 4CHRISTUS Stehlin Foundation for Cancer Research, Houston, TX, USA*These authors contributed equally to this work†Dr Beppino C Giovanella passed away in 2017.Background and aim: We have synthesized a novel lactone-stabilized camptothecin (CPT) analog named CZ48 and demonstrated its potent anticancer effects via bioconversion to the active CPT in earlier studies. Herein, we aimed to develop, optimize and characterize CZ48 nanosuspensions, for a sustained delivery of this drug in humans with an intravenous (i.v.) administration.Methods and materials: A three-factor, five-level central composite design (CCD) was employed to establish the impacts of the critical influencing factors (concentrations (wt%) of CZ48, polysorbate 80 (Tween-80), and Pluronic®, F-108 (F-108)) on the responses (particle size and zeta potential). Based on the quantitative influencing factor–response relationships, two optimized CZ48 nanosuspensions of 197.22 ± 7.12 nm (NS-S) and 589.35 ± 23.27 nm (NS-L) were developed with the zeta potential values of –26.5 mV and –27.9 mV, respectively.Results: CZ48 released from the nanosuspensions in a sustained manner in contrast to the rapid release from cosolvent in both PBS and human plasma. Moreover, NS-S exhibited more favored pharmacokinetic properties than NS-L, with a 31-fold prolonged elimination half-life of CPT, and a 2.4-fold enhanced CPT exposure over cosolvent. In efficacy study, NS-S exhibited significant tumor suppression and an improved survival rate with a higher tolerable dose, compared to CZ48 cosolvent.Conclusion: We have successfully developed CZ48 nanosuspensions with significantly favorable pharmacokinetics and improved efficacy using CCD approach. The formulation offers potential merits as a preferred candidate for clinical trials with the prolonged CPT exposure, which is known to correlate with the clinical efficacy.Keywords: sustained drug delivery, CZ48, camptothecin, nanosuspension, anticancer |
| format |
article |
| author |
Dong D Hsiao CH Giovanella BC Wang Y Chow DSL Li Z |
| author_facet |
Dong D Hsiao CH Giovanella BC Wang Y Chow DSL Li Z |
| author_sort |
Dong D |
| title |
Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| title_short |
Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| title_full |
Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| title_fullStr |
Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| title_full_unstemmed |
Sustained delivery of a camptothecin prodrug – CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| title_sort |
sustained delivery of a camptothecin prodrug – cz48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/ad81c71594a64c578accf6db73e8b5ae |
| work_keys_str_mv |
AT dongd sustaineddeliveryofacamptothecinprodrugndashcz48bynanosuspensionswithimprovedpharmacokineticsandenhancedanticanceractivity AT hsiaoch sustaineddeliveryofacamptothecinprodrugndashcz48bynanosuspensionswithimprovedpharmacokineticsandenhancedanticanceractivity AT giovanellabc sustaineddeliveryofacamptothecinprodrugndashcz48bynanosuspensionswithimprovedpharmacokineticsandenhancedanticanceractivity AT wangy sustaineddeliveryofacamptothecinprodrugndashcz48bynanosuspensionswithimprovedpharmacokineticsandenhancedanticanceractivity AT chowdsl sustaineddeliveryofacamptothecinprodrugndashcz48bynanosuspensionswithimprovedpharmacokineticsandenhancedanticanceractivity AT liz sustaineddeliveryofacamptothecinprodrugndashcz48bynanosuspensionswithimprovedpharmacokineticsandenhancedanticanceractivity |
| _version_ |
1718399956478328832 |